Journal
BLOOD
Volume 115, Issue 25, Pages 5164-5169Publisher
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2010-01-263145
Keywords
-
Categories
Funding
- CCR NIH HHS [HHSN261200800001C] Funding Source: Medline
- Intramural NIH HHS Funding Source: Medline
- NCI NIH HHS [HHSN261200800001E] Funding Source: Medline
Ask authors/readers for more resources
Autoimmune lymphoproliferative syndrome (ALPS) is characterized by childhood onset of lymphadenopathy, hepatosplenomegaly, autoimmune cytopenias, elevated numbers of double-negative T (DNT) cells, and increased risk of lymphoma. Most cases of ALPS are associated with germline mutations of the FAS gene (type Ia), whereas some cases have been noted to have a somatic mutation of FAS primarily in their DNT cells. We sought to determine the proportion of patients with somatic FAS mutations among a group of our ALPS patients with no detectable germline mutation and to further characterize them. We found more than one-third (12 of 31) of the patients tested had somatic FAS mutations, primarily involving the intracellular domain of FAS resulting in loss of normal FAS signaling. Similar to ALPS type Ia patients, the somatic ALPS patients had increased DNT cell numbers and elevated levels of serum vitamin clinical and laboratory phenotype to that of ALPS type Ia. These findings also highlight the potential role for somatic mutations in the pathogenesis of nonmalignant and/or autoimmune hematologic conditions in adults and children. (Blood. 2010; 115(25):5164-5169)
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available